Our Mission

Eric Pierce MD PhD and Jason Comander MD PhD and Rachel Huckfeldt MD PhD in an eye exam room all in discussion

Striving to find treatments for rare eye disease, Odylia Therapeutics is dedicated to facilitating the movement of science from the lab into the clinic to save vision for those going blind due to Inherited Retinal Disease.  Our mission is to change the paradigm of how rare disease treatments are brought through clinical trials.  By leveraging our 501(c)(3) status, we can significantly lower costs through partner discounts and economies of scale in manufacturing, pharm/tox and other needed services.  As a non-profit entity, we can reduce time tables for moving through clinical trials. Because we are non-competitive, outside commercial sponsors can use Odylia as a de-risked environment in which to operate, encouraging treatments for diseases with smaller prevalence.

Questions? We’re here to help!